Board of Directors

Erik Amble

Director

Erik Amble is the Founder and Chairman of NeoMed Management. He has over 30 years’ experience of venture capital investing in Europe and the US, with the last 25 years in the healthcare industry. Previously Erik was Chairman of NeoMed AS, an investment advisory firm specialized in the healthcare industry, and President of Origo Ventures AS, a Norwegian private equity firm. Erik is a cofounder and former Chairman of the Norwegian Venture Capital Association.

Since founding NeoMed, he has been a board member of a number of emerging healthcare companies based in Europe and the US. He currently serves on the board of directors of Axonics Modulation Technologies, JenaValve Technology, CorFlow Therapeutics, Sequana Medical and SERCA Pharmaceuticals.

Erik holds a Master of Science degree in Management from the Graduate School of Business, Stanford University, USA, and a Doctor of Science degree in Organic Chemistry from the University of Oslo, Norway.

Juliet Tammenoms Bakker

Director

Ms. Bakker is a Managing Director and Founder of Longitude Capital. Prior to Longitude Capital, Ms. Bakker was a Managing Director of Pequot Ventures, where she founded the life sciences investment practice. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International. Previously, she was a sell-side equity analyst with Banque Paribas. Ms. Bakker began her career as an investment banker in the corporate finance department at PaineWebber. She currently serves on the boards of Alphaeon, Axonics Modulation Technologies (AXNX), DyaMX, Encore Dermatology, Nalu, RxSight and Venus Concept. She has previously served on the boards of Ablation Frontiers (acquired by Medtronic), AqueSys (acquired by Allergan), CryoVascular Systems (acquired by Boston Scientific), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R.Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), and Sadra Medical (acquired by Boston Scientific). Ms. Bakker holds an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University (“CALS”), where she is a member of the CALS Advisory Council. Ms. Bakker is also a board member of the Boys and Girls Club of Greenwich.

Michael H. Carrel

Chairman of the Board

Michael H. Carrel has served on the board of Axonics Modulation Technologies, Inc. since March 4, 2019.

Mr. Carrel is President and Chief Executive Officer of AtriCure (NASDAQ: ATRC), a medical device company that provides innovative solutions for the treatment of atrial fibrillation (AFib) and related conditions. Since joining AtriCure, the company has significantly invested in groundbreaking clinical trials for the treatment of AFib, left atrial appendage management and pain management; expanded its market presence within Europe and Asia; and grown the global employee base from 200 to over 600 employees. Under his leadership, AtriCure has acquired two companies, Estech and nContact, adding leading ablation technologies to further its market position worldwide. Mr. Carrel also serves on the Board of Medical Device Manufacturers Association (MDMA).

Before joining AtriCure, Mr. Carrel was President and Chief Executive Officer of Vital Images, a publicly-traded medical imaging software company, President and CEO of Zamba Corp., a publicly-traded technology company, and Chief Financial Officer of NextNet Wireless, a privately-held provider of non-line-of-sight plug-and-play broadband wireless access systems.

Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from the Wharton School at the University of Pennsylvania. Mr. Carrel has been the Chairman of the Board of Axonics since 2020.

Raymond W. Cohen

Director, CEO at Axonics Modulation Technologies

Mr. Cohen has served as CEO and member of the board of directors since co-founding Axonics in October 2013. Mr. Cohen is an accredited public company director with over 35 years of experience in leading medical-device companies and serving as a board member at a number of private and publicly traded life science companies. From 2010 to 2012, he served as CEO of venture capital-backed Vessix Vascular, which was acquired by Boston Scientific in November 2012. Previously, Mr. Cohen spent nearly a decade as Chairman and CEO of Nasdaq-listed Cardiac Science Inc., which was ranked as the fourth-fastest growing company in the US in 2004. Currently, Mr. Cohen serves as the Chairman of the board of directors at BioLife Solutions (Nasdaq: BLFS – preservation media for regenerative medicine). From June 2013 to April 2020, he served as an independent director, Chair of the compensation committee and member of the audit and nominating committees of Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI – Oncology drugs). Mr. Cohen also previously served on the boards of two companies that successfully executed an exit transaction in 2017, Zurich-based LifeWatch (LIFE.SW), sold to Biotelemetry (Nasdaq: BEAT); and Colorado-based Syncroness, Inc. (privately held contract engineering firm), sold to ALTEN Group, a multibillion-dollar French engineering services company.

Jane E. Kiernan

Independent Director

Jane E. Kiernan has over 30 years of executive and management leadership in healthcare with both public and private companies. Kiernan joined the Axonics Modulation Technologies, Inc. Board of Directors on April 8, 2019 and serves on the Audit Committee. Kiernan is a cofounder of K2 Biotechnology Ventures, an organization engaged in developing and commercializing university and medical center innovations in partnership with venture capital, healthcare corporations and philanthropic healthcare foundation partners. From 2010–2017, Kiernan served as the CEO of Salter Labs, a manufacturer of specialty medical devices with approximately 1,000 employees and $85 million in annual revenue. From 2006–2011, Kiernan served on the Board of Directors and as Chair of the Audit Committee of Nasdaq-listed American Medical Systems (AMS) prior to AMS being acquired by Endo Pharmaceuticals (NASDAQ: ENDP) for $2.9 billion. From 2001–2010, Kiernan held executive and general management positions with profit and loss responsibility for as much as $1.5 billion in revenue with both Baxter Healthcare Corporation and Allegiance Healthcare Corporation. As a community leader, Kiernan serves on the Board of Directors for Ryan Banks Academy and has served on the Board of Directors of the American Red Cross of Greater Chicago. In addition, she is a past President of the Healthcare Businesswomen’s Association, Chicago Chapter. Kiernan holds a B.S. degree in business from Southern Methodist University.

Robert McNamara

Independent Director

Robert McNamara has served as Axonics' Audit Committee Chairman since November 2018. He is an accomplished senior executive with demonstrated success in public and privately held companies with global operations in highly competitive industries, including medical device, software and high technology. He has extensive experience in initial public offerings (IPOs), mergers and acquisitions (M&A), operations and financial management at early stage, high growth and mature companies. Mr. McNamara has raised significant capital (more than $500M) in public offerings and private placements, while managing investor relations, international operations and strategic planning. As CFO, he has managed and led three IPOs, six acquisitions/mergers, including two exceeding $1B each, and numerous rounds of venture capital funding. In 2015, he was named Acquisition International Magazine’s Texas Healthcare CFO of the Year. He has been the EVP/CFO of four public medical device companies. He is currently a member of the Board of Directors for Xtant Medical, chairs its Compensation Committee and is a member of its Audit Committee. In addition, he was elected council member and served as mayor of Menlo Park, CA.

Mr. McNamara is a CPA (nonpracticing). He has a B.S. from University of San Francisco and an M.B.A. from University of Pennsylvania’s Wharton School.

Nancy L. Snyderman, MD

Independent Director

Dr. Nancy Snyderman is a renowned surgeon, healthcare systems expert, and corporate director. Dr. Snyderman currently serves on the boards of Alkermes (NASDAQ: ALKS) and Axonics Modulation Technologies (NASDAQ: AXNX).

She serves as a Scientific Advisor to start-up companies Cadence and Strand Diagnostics. She sits on the boards of the Albright Institute at Wellesley College and the Fair Food Network. Dr. Snyderman is a Kellogg Fellow and Fellow in the American College of Surgeons. Her career includes 15 years working on innovative medical programs and products for General Electric and Johnson & Johnson. She began her corporate career in 2003 at Johnson & Johnson, where she created online medical curricula that J&J marketed to the public. For 10 years, Dr. Snyderman served on the board of General Electric’s Healthymagination, which applied technology solutions to the world’s biggest health challenges.

For more than 30 years Dr. Snyderman was an award-winning Senior Medical Editor at ABC and NBC News. Her skills uniquely span the fields of medicine, science, communication, and global media. Dr. Snyderman spent 25 years as a board-certified, practicing Otolaryngologist-Head and Neck Surgeon at UC San Francisco and the University of Pennsylvania.

With deep expertise on the intersection of medicine, big data and the media, Dr. Snyderman recently served as a Consulting Professor at the Stanford University Center for Innovation in Global Health and is cofounder of the Stanford University-NBC News Global Media Fellowship.

Dr. Snyderman is a New York Times bestselling author and has traveled the globe extensively, lecturing and reporting from some of the world’s most troubled areas. Her reporting has garnered her the industry’s most distinguished honors including Emmy, DuPont, Edward R. Murrow, and Gracie awards.

Questions?

We are here to help answer any questions you may have about the Axonics System and Therapy.